Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19248284 | 0.87 | KMT2A (0.46) | TSHRHSD17B10LMNAKMT2ANLRP3 | |
| SCHEMBL19696800 | 0.83 | HSD17B10 (0.52) | TSHRHSD17B10LMNAKMT2ANLRP3 | |
| SCHEMBL12355338 | 0.81 | LMNA (0.44) | TSHRHSD17B10LMNAKMT2ANLRP3 | |
| SCHEMBL18100131 | 0.78 | LMNA (0.40) | TSHRHSD17B10LMNAKMT2ANLRP3 | |
| SCHEMBL3466415 | 0.74 | SMN1; SMN2 (0.62) | TSHRHSD17B10LMNAKMT2ANLRP3 | |
| SCHEMBL18100134 | 0.73 | CA1 (0.37) | TSHRLMNAKMT2ANLRP3MEN1 | |
| SCHEMBL18100130 | 0.73 | CA2 (0.45) | TSHRLMNAKMT2ANLRP3MEN1 | |
| SCHEMBL18100133 | 0.71 | LMNA (0.35) | TSHRHSD17B10LMNAKMT2ANLRP3 | |
| SCHEMBL26006919 | 0.71 | TSHR (0.48) | TSHRHSD17B10LMNAKMT2ANLRP3 | |
| SCHEMBL11750990 | 0.69 | KMT2A (0.59) | TSHRHSD17B10LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735416-B2 | Antiviral therapies | TECHNISCHE UNIVERSITAET CAROLO-WILHELMINA ZU BRAUNSCHWEIG (DE) | 2014-05-27 | — | — | US | disclosed |
| US-20140113923-A1 | NOVEL ANTIVIRAL THERAPIES | TECHNISCHE UNIVERSITAET CAROLO-WILHELMINA ZU BRAUNSCHWEIG (DE) | 2014-04-24 | — | — | US | disclosed |
| US-8193157-B2 | Antiviral therapies | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-06-05 | — | — | US | disclosed |
| US-20090042793-A1 | Novel Antiviral Therapies | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042793-A1 | Novel Antiviral Therapies | HAVCR2, LGALS3BP, MAVS | TSHR 3758/4885HSD17B10 754/4885LMNA 1261/4885 |
| US-20140113923-A1 | NOVEL ANTIVIRAL THERAPIES | HAVCR2, LGALS3BP, LGALS4 | TSHR 3327/4885HSD17B10 691/4885LMNA 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.